Last updated on February 2018

CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Brief description of study

This study is to determine the maximum tolerated dose(MTD) and recommened phase 2 dose(RP2D) based on dose limiting toxicity(DLT), and to evaluate safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Lenalidomide and Dexamethasone in patients with Previously Treated Multiple Myeloma.

Detailed Study Description

This is an open label, dose escalation study. Cohort of 3~6 patients receive escalation doses of CKD-516 until the maximum tolerated dose(MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.

Clinical Study Identifier: NCT03150316

Find a site near you

Start Over

Samsung Hospital

Soul, Korea, Republic of
  Connect »